We’re proud to share that the Financial Times has published a letter from SIME, responding to the wider debate on demographics and delayed childbirth.
In the context of falling fertility rates and people having children later in life, the conversation often centres on economics: housing, childcare, workforce dynamics, and long-term growth. Our letter highlights something that’s often missing from that discussion: Maternal and newborn health isn’t a niche issue. It’s long-term economic infrastructure.
As childbirth shifts later, biological risks for both mother and baby rise. At the same time, as birth rates decline, each child carries greater future economic weight. Yet innovation and investment still disproportionately target diseases of later life. While early-life health is too often treated as secondary.
In the letter, we make the case that preventable complications in pregnancy and early infancy don’t just affect families. They shape: long-term health outcomes, future workforce participation and productivity, healthcare costs over decades and broader economic resilience.
The commercial reality people underestimate
Maternal and neonatal care are sometimes labelled “small markets.” But the truth is: the cost of complications is so high that the willingness to invest in prevention and earlier diagnosis is also high. That disconnect suggests a wider misalignment between capital allocation and long-term value.
Why we’re sharing this
At SIME Diagnostics, we’re building with this exact lens: earlier, biology-informed insight in newborn care, so clinicians can make faster, clearer decisions—and more babies can get the right support at the right time.
Read the letter on the Financial Times:
Read the FULL letter on the FINANCIAL TIMES